

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

○ 미국 77건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04827979	Daratumumab and Belatacept for Desensitization	Highly Sensitized Prospective Kidney Transplant Recipients	Biological: daratumumab Drug: belatacept Procedure: Bone marrow aspiration	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) Bristol-Myers Squibb PPD Rho Federal Systems Division, Inc.	Phase 1 Phase 2	
NCT04784052	Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing JSP191	Fanconi Anemia	Drug: JSP191 Device: CliniMACS Prodigy System Biological: Depleted Stem Cell Transplant Biological: Rabbit Anti-Thymoglobulin (rATG) Drug: Cyclophosphamide Drug: Fludarabine Drug: Rituximab	Maria Grazia Roncarolo Stanford University	Phase 1 Phase 2	
NCT04751331	Neural Response to Inflammatory Challenge in Major Depressive Disorder	Major Depressive Disorder	Biological: LPS Biological: Saline	Laureate Institute for Brain Research, Inc.	Phase 1 Phase 2	
NCT04709705	DSMO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)	Cardiac Surgery	Biological: Human platelets	Cellphire, Inc. U.S. Army Medical Research and Development Command	Phase 2 Phase 3	
NCT04684641	Cystic Fibrosis bacterioPHage Study at Yale (CYPHY)	Cystic Fibrosis	Drug: Standard Dose YPT-01 Other: Placebo	Yale University	Phase 1 Phase 2	
NCT04652908	Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial	Myelomeningocele	Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix	Diana Lee Farmer California Institute for Regenerative Medicine (CIRM) University of California, Davis	Phase 1 Phase 2	
NCT04624113	Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	Drug: Tazemetostat Drug: Pembrolizumab	Washington University School of Medicine Epizyme, Inc.	Phase 1 Phase 2	
NCT04563195	BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome	Primary Sjogren's Syndrome	Drug: tibulizumab (LY3090106)	Matthew C. Baker Stanford University	Phase 2 Phase 3	
NCT04199728	Use of a GLP-1R Agonist to Treat Opioid Use Disorder	Opiate Substitution Treatment Opioid-Related Disorders	Drug: Liraglutide Pen Injector Drug: Placebo	Milton S. Hershey Medical Center National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA)	Phase 1 Phase 2	
NCT03991299	Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects	Obese Diabetes Mellitus, Type 2	Drug: Botox 200 UNT Injection	Vanderbilt University Medical Center	Phase 1 Phase 2	
NCT04825223	Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants	Meningococcal Immunisation	Drug: Multicomponent Meningococcal B Vaccine Drug: Meningococcal Group B Vaccine MenB Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed) Drug: Placebo Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine	Sanofi Pasteur, a Sanofi Company Sanofi	Phase 1 Phase 2	
NCT04826224	CAM Procedure With BMAC for Shoulder OA	Shoulder Osteoarthritis	Biological: Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.	Shane A. Shapiro Mayo Clinic	Phase 1	
NCT04821648	RJV001 Study in Adults Receiving Abdominoplasty	Submental Fat (SMF) Double Chin	Drug: RJV001	Rejuven Dermaceutical Co., Ltd.	Phase 1	
NCT04816526	Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy	Myeloma Multiple	Biological: Descartes 08	Cartesian Therapeutics	Phase 2	
NCT04808999	Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)	Squamous Cell Carcinoma	Drug: Pembrolizumab Injection	Diwakar Davar Merck Sharp & Dohme Corp. University of Pittsburgh	Phase 2	
NCT04804891	Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation	Intestinal Transplantation	Biological: Cell Therapy	Columbia University Ossium Health	Phase 1	
NCT04802031	Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma	Relapsed Multiple Myeloma Refractory Multiple Myeloma	Biological: Rapid Infusion Isatuximab	Thomas Martin, MD University of California, San Francisco	Phase 2	
NCT04782687	Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma	Multiple Myeloma Myeloma Multiple Kahler Disease Myeloma, Plasma Cell Myeloma-Multiple Myelomatosis Plasma Cell Myeloma	Drug: Selinexor Drug: Dexamethasone Oral Drug: Daratumumab Drug: Lenalidomide	US Oncology Research Karyopharm Therapeutics Inc	Phase 2	
NCT04781088	Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Endometrial Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma	Drug: Lenvatinib Drug: Paclitaxel Biological: Pembrolizumab	Floor Backes Ohio State University Comprehensive Cancer Center	Phase 2	
NCT04765449	Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection	Covid19	Drug: Cytotoxic T Lymphocytes	Thomas Jefferson University Tevogen Bio Inc	Phase 1	
NCT04761614	Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Bevacizumab Drug: Fluorouracil Drug: Leucovorin Calcium Drug: Oxaliplatin Drug: Riluzole	Ning Jin Ohio State University Comprehensive Cancer Center	Phase 1	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

NCT04756505	Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial	Anatomic Stage IV Breast Cancer AJCC v8 Hormone Receptor Positive Breast Adenocarcinoma Metastatic Breast Carcinoma Metastatic HER2 Negative Breast Adenocarcinoma Prognostic Stage IV Breast Cancer AJCC v8	Drug: Bintrafusp Alfa Biological: Immunocytokine NHS-IL12 Radiation: Radiation Therapy	M.D. Anderson Cancer Center	Phase 1	
NCT04753879	Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.	Metastatic Pancreatic Cancer	Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Cisplatin Drug: Irinotecan Drug: Capecitabine Drug: Pembrolizumab Drug: Olaparib	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme Corp.	Phase 2	
NCT04748042	Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)	Prostate Cancer Castrate Sensitive Prostate Cancer Oligometastatic Disease	Drug: Abiraterone Drug: Prednisone Radiation: External Beam Radiotherapy Biological: Androgen Deprivation Therapy (ADT) Drug: Olaparib	University of Michigan Rogel Cancer Center	Phase 2	
NCT04745949	PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy	Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma	Drug: Brentuximab Vedotin Drug: Cyclophosphamide Drug: Doxorubicin Biological: Nivolumab Drug: Prednisone Other: Quality-of-Life Assessment Biological: Rituximab	M.D. Anderson Cancer Center	Phase 2	
NCT04731272	GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance	Cystic Fibrosis Pancreatic Insufficiency Abnormal Glucose Tolerance Diabetes	Drug: Dulaglutide 0.75Mg/0.5Ml Inj Pen	University of Pennsylvania Children's Hospital of Philadelphia	Phase 2	
NCT04722003	Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination	Gonorrhoea	Biological: Meningococcal Group B Vaccine Other: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	
NCT04714372	FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia	Acute Myeloid Leukemia Myeloid Leukemia Monocytic Leukemia	Drug: Daratumumab/rHuPH20 Drug: FT538 Drug: Fludarabine Drug: Cyclophosphamide	Masonic Cancer Center, University of Minnesota	Phase 1	
NCT04710498	Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	Drug: Atezolizumab	Stanford University Genentech, Inc.	Phase 2	
NCT04684563	huCART19-IL18 in NHL/CLL Patients	Chronic Lymphocytic Leukemia Non-hodgkin Lymphoma	Biological: huCART19-IL18	University of Pennsylvania	Phase 1	
NCT04680468	Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma	Myeloma	Drug: Belantamab mafodotin	Abramson Cancer Center of the University of Pennsylvania GlaxoSmithKline	Phase 2	
NCT04677829	Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)	Traumatic Brain Injury	Biological: PNT001 Biological: %5 dextrose for infusion	Pinteon Therapeutics, Inc	Phase 1	
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 BRCA-Mutated Malignant Neoplasm BRCA-Mutated Metastatic Breast Carcinoma BRCA-Mutated Ovarian Carcinoma Metastatic Breast Carcinoma Metastatic Fallopian Tube Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Ovarian Carcinoma Metastatic Pancreatic Carcinoma Metastatic Primary Peritoneal Carcinoma Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8 Unresectable Breast Carcinoma Unresectable Fallopian Tube Carcinoma Unresectable Malignant Solid Neoplasm Unresectable Ovarian Carcinoma Unresectable Pancreatic Carcinoma Unresectable Primary Peritoneal Carcinoma	Biological: Dostarlimab Drug: Niraparib	University of Washington GlaxoSmithKline	Phase 1	
NCT04670068	Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian	Epithelial Ovarian Cancer	Drug: CAR.B7-H3 Drug: Fludarabine Drug: Cyclophosphamide	UNC Lineberger Comprehensive Cancer Center National Institutes of Health (NIH)	Phase 1	
NCT04653246	Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma	Multiple Myeloma Newly Diagnosed Multiple Myeloma (NDMM) Autologous Stem Cell Transplant	Drug: Isatuximab Drug: Lenalidomide Drug: Bortezomib Injection Drug: Dexamethasone	Jacob Laubach Sanofi Dana-Farber Cancer Institute	Phase 2	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

NCT04643379	Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma	Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma	Drug: Olaparib Drug: Pembrolizumab Drug: Carboplatin Procedure: Peripheral blood draw	Washington University School of Medicine Merck Sharp & Dohme Corp. Joseph Sanchez Foundation	Phase 2	
NCT04635683	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Lymphoplasmacytic Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Nodal Marginal Zone Lymphoma Recurrent Splenic Marginal Zone Lymphoma Recurrent Waldenstrom Macroglobulinemia Refractory B-Cell Non-Hodgkin Lymphoma Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Refractory Follicular Lymphoma Refractory Grade 1 Follicular Lymphoma Refractory Grade 2 Follicular Lymphoma Refractory Grade 3a Follicular Lymphoma Refractory Lymphoplasmacytic Lymphoma Refractory Mantle Cell Lymphoma Refractory Marginal Zone Lymphoma Refractory Nodal Marginal Zone Lymphoma Refractory Splenic Marginal Zone Lymphoma Refractory Waldenstrom Macroglobulinemia	Drug: Lenalidomide Biological: Ublituximab Drug: Umbralisib	Yazeed Sawalha Ohio State University Comprehensive Cancer Center	Phase 1	
NCT04606914	Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Ovarian Cancer Fallopian Tube Primary Peritoneal Cancer	Drug: mirvetuximab soravtansine (MIRV; IMGN853)	University of Alabama at Birmingham	Phase 2	
NCT04572451	Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors	Melanoma Carcinoma, Renal Cell Unresectable Solid Tumors	Drug: nivolumab Drug: BMS-986253 Radiation: Stereotactic Body Radiotherapy (SBRT)	Jason J. Luke, MD Bristol-Myers Squibb University of Pittsburgh	Phase 1	
NCT04571203	Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment	Immune Tolerance	Biological: Combined Deceased Donor Kidney and Hematopoietic Cell Transplants	Stanford University	Phase 1	
NCT04560972	LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer	Extensive Stage Lung Small Cell Carcinoma	Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Protein Phosphatase 2A Inhibitor LB-100	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	
NCT04510428	OSIG-eye Drops Treatment for Dry Eye Disease	Dry Eye	Drug: Ocular Surface Immune Globulin (OSIG) Drug: Placebo	Sandeep Jain, MD University of Illinois at Chicago	Phase 2	
NCT04465643	Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor	Nerve Sheath Tumors	Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1	
NCT04430452	Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition	Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8	Biological: Durvalumab Radiation: Hypofractionated Radiation Therapy Biological: Tremelimumab	Mary Feng, MD AstraZeneca University of California, San Francisco	Phase 2	
NCT04419909	Retreatment With CTL019/CTL119	Lymphoma, B-Cell	Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)	University of Pennsylvania	Phase 1	
NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2	
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute	Phase 2	
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Urologic Diseases Male Urogenital Diseases Urethral Stricture Urethral Injury	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1	
NCT03068832	Neopeptide-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Pediatric Brain Tumor	Biological: Personalized peptide vaccine Drug: Poly ICLC Procedure: Peripheral blood draw	Washington University School of Medicine	Phase 1	
NCT04823702	Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function	Impaired Hepatic Function	Biological: Aldafermin	NGM Biopharmaceuticals, Inc	Phase 1	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

NCT04798001	Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults	Covid19	Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray	Meissa Vaccines, Inc.	Phase 1	
NCT04739059	Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks	Hereditary Angioedema	Biological: CSL312	CSL Behring	Phase 3	
NCT04637763	CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma	Lymphoma, Non-Hodgkin Relapsed Non Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma Lymphoma B Cell Lymphoma B Cell Non-Hodgkin's Lymphoma	Genetic: CB-010 Drug: Cyclophosphamide Drug: Fludarabine	Caribou Biosciences, Inc.	Phase 1	
NCT04448834	Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphia CD19+ ALL	B-cell Acute Lymphoblastic Leukemia	Drug: Blinatumomab	David Rizzieri, MD Amgen Acrotech Biopharma LLC Duke University	Phase 2	
NCT04537377	A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease	Wilson's Disease	Genetic: VTX-801	Vivet Therapeutics SAS	Phase 1 Phase 2	
NCT04658472	Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Drug: BIVV020	Sanofi	Phase 2	
NCT04624633	AU2 In Relapsed and Untreated CLL	Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Relapsed Chronic Lymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia	Drug: Acalabrutinib Drug: Ubrutinib Drug: Ublituximab	Jennifer R. Brown, MD, PhD AstraZeneca TG Therapeutics, Inc. Dana-Farber Cancer Institute	Phase 2	
NCT04426591	Red Blood Cell Survival in Sickle Cell Disease	Sickle Cell Disease	Drug: Biotin Labeled Red Blood Cells	Emory University National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	
NCT04785144	Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults	COVID-19 COVID-19 Immunisation	Biological: mRNA-1273 Biological: mRNA-1273.351	National Institute of Allergy and Infectious Diseases (NIAID) ModernaTX, Inc.	Phase 1	
NCT04676477	Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer (NSCLC)	Drug: Patritumab deruxtecan Drug: Osimertinib	Daiichi Sankyo, Inc.	Phase 1	
NCT04673617	AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Non Hodgkin Lymphoma	Drug: AB-101 Drug: Rituximab Drug: Interleukin-2 Drug: Cyclophosphamide Drug: Fludarabine	Artiva Biotherapeutics, Inc.	Phase 1 Phase 2	
NCT04824092	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients	Diffuse Large B-cell Lymphoma	Drug: Tafasitamab Drug: Lenalidomide Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Tafasitamab placebo Drug: Lenalidomide placebo	MorphoSys AG	Phase 3	
NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	Non-alcoholic Steatohepatitis	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	
NCT04816669	Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults	SARS-CoV-2 Infection COVID-19	Biological: BNT162b2	BioNTech SE Pfizer	Phase 3	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	
NCT04756401	Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma	Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma	Drug: Carfilzomib Biological: Daratumumab Drug: Dexamethasone Other: Quality-of-Life Assessment Drug: Selinexor	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

NCT04660760	Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVA Gastric Cancer AJCC v8 Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVB Gastric Cancer AJCC v8 Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 Locally Advanced Unresectable Gastric Adenocarcinoma Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Pathologic Stage III Gastric Cancer AJCC v8 Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIA Gastric Cancer AJCC v8 Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIB Gastric Cancer AJCC v8 Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIC Gastric Cancer AJCC v8 Pathologic Stage IV Gastric Cancer AJCC v8 Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8 Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8 Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8	Drug: Paclitaxel Other: Quality-of-Life Assessment Biological: Ramucirumab Drug: Trifluridine and Tipiracil Hydrochloride	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	
NCT04680052	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.	Follicular Lymphoma Marginal Zone Lymphoma	Drug: tafasitamab Drug: rituximab Drug: lenalidomide Drug: placebo	Incyte Corporation	Phase 3	
NCT04622007	Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy	Non-small Cell Lung Cancer	Drug: Tomivosertib Biological: Pembrolizumab	Effector Therapeutics Medpace, Inc.	Phase 2	
NCT04495010	Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants	Melanoma	Biological: Nivolumab Biological: Ipilimumab	Bristol-Myers Squibb	Phase 2	
NCT04722172	A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL	Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma	Drug: Acalabrutinib Drug: Obinutuzumab	Memorial Sloan Kettering Cancer Center AstraZeneca Genentech, Inc.	Phase 2	
NCT04260126	Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC	Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer HPV Positive Oropharyngeal Squamous Cell Carcinoma HPV-Related Esophageal Squamous Cell Carcinoma Neoplasms, Head and Neck	Combination Product: Pembrolizumab and PDS0101	PDS Biotechnology Corp. Merck Sharp & Dohme Corp.	Phase 2	
NCT04683003	A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755	Congenital Thrombotic Thrombocytopenic Purpura	Biological: TAK-755	Takeda Shire	Phase 3	
NCT04659629	NL-201 in Patients With Relapsed or Refractory Cancer	Solid Tumor Advanced Solid Tumor	Drug: NL-201	Neoleukin Therapeutics, Inc.	Phase 1	

○ 영국 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04704830	R21/Matrix-M in African Children Against Clinical Malaria	Malaria	Biological: R21/Matrix-M Biological: Rabies vaccine	University of Oxford Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest Malaria Research and Training Center, Bamako, Mali KEMRI-Wellcome Trust Collaborative Research Program Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania London School of Hygiene and Tropical Medicine	Phase 3	
NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	Non-alcoholic Steatohepatitis	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

NCT04824092	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients	Diffuse Large B-cell Lymphoma	Drug: Tafasitamab Drug: Lenalidomide Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Tafasitamab placebo Drug: Lenalidomide placebo	MorphoSys AG	Phase 3	
NCT04495010	Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants	Melanoma	Biological: Nivolumab Biological: Ipilimumab	Bristol-Myers Squibb	Phase 2	
NCT04790916	Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)	Autoimmune Hepatitis Autoimmune Chronic Hepatitis	Drug: RO7049665 Other: Placebo	Hoffmann-La Roche	Phase 2	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	
NCT04683003	A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755	Congenital Thrombotic Thrombocytopenic Purpura	Biological: TAK-755	Takeda Shire	Phase 3	

○ 프랑스 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04651439	Severe Bullous Drug Eruption and Filgrastim	Rare Diseases Toxic Epidermal Necrolyses	Drug: Filgrastim Drug: Placebo	Hospices Civils de Lyon	Phase 2 Phase 3	
NCT04751877	Study of Isatuximab+Lenalidomide+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients	Multiple Myeloma Myeloma	Drug: Isatuximab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone	Poitiers University Hospital Intergroupe Francophone du Myelome	Phase 3	
NCT04705818	Combining Epigenetic And Immune Therapy to Beat Cancer.	Advanced Solid Tumor Advanced Colorectal Carcinoma Advanced Soft-tissue Sarcoma Advanced Pancreatic Adenocarcinoma Adult Solid Tumor	Drug: Durvalumab Drug: Tazemetostat	Institut Bergonié AstraZeneca Epizyme, Inc.	Phase 2	
NCT04824092	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients	Diffuse Large B-cell Lymphoma	Drug: Tafasitamab Drug: Lenalidomide Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Tafasitamab placebo Drug: Lenalidomide placebo	MorphoSys AG	Phase 3	
NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	Non-alcoholic Steatohepatitis	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	
NCT04495010	Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants	Melanoma	Biological: Nivolumab Biological: Ipilimumab	Bristol-Myers Squibb	Phase 2	
NCT04683003	A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755	Congenital Thrombotic Thrombocytopenic Purpura	Biological: TAK-755	Takeda Shire	Phase 3	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	

○ 독일 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04803994	The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma	Hepatocellular Carcinoma	Drug: Atezolizumab Drug: Bevacizumab Procedure: TACE	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 3	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.
출처: ClinicalTrials.gov

NCT04808245	A Multicenter Phase I Peptide Vaccine Trial for the Treatment of H3-Mutated Gliomas	Newly Diagnosed H3-mutated Glioma	Drug: Tecentriq 1200 MG in 20 ML Injection Biological: H3K27M peptide vaccine Other: Imiquimod (5%)	German Cancer Research Center Johannes Gutenberg University Mainz Charite University, Berlin, Germany Roche Pharma AG German Cancer Aid	Phase 1	
NCT04824092	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients	Diffuse Large B-cell Lymphoma	Drug: Tafasitamab Drug: Lenalidomide Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Tafasitamab placebo Drug: Lenalidomide placebo	MorphoSys AG	Phase 3	
NCT04495010	Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants	Melanoma	Biological: Nivolumab Biological: Ipilimumab	Bristol-Myers Squibb	Phase 2	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	
NCT04790916	Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)	Autoimmune Hepatitis Autoimmune Chronic Hepatitis	Drug: RO7049665 Other: Placebo	Hoffmann-La Roche	Phase 2	
NCT04683003	A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755	Congenital Thrombotic Thrombocytopenic Purpura	Biological: TAK-755	Takeda Shire	Phase 3	

○ 중국 23건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04803539	A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC	Breast Cancer	Drug: capecitabine Drug: capecitabine + camrelizumab + apatinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Jiangsu HengRui Medicine Co., Ltd.	Phase 2 Phase 3	
NCT04796857	Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL	Non-GCB/ABC Diffuse Large B-Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma Grade IIIb Transformed Lymphoma EBV-Positive DLBCL, Nos ALK-Positive Anaplastic Large Cell Lymphoma	Drug: PD-1 Antibody Drug: Lenalidomide	Huiqiang Huang Sun Yat-sen University	Phase 1 Phase 2	
NCT04828174	Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies	Peripheral T Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Anaplastic Lymphoma Acute T Cell Leukemia T-lymphoblastic Lymphoma	Drug: anti-TRBC1 CAR-T cell therapy	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 1	
NCT04826679	Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC	Head and Neck Squamous Cell Carcinoma	Drug: Camrelizumab, nab-paclitaxel, cisplatin	Sun Yat-sen University Jiangsu HengRui Medicine Co., Ltd.	Phase 2	
NCT04815408	PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer	Ovarian Cancer Neoadjuvant Chemotherapy Anti-PD-1 Neoadjuvant Immunotherapy	Drug: BGB-A317 Drug: albumin-bound paclitaxel 260mg/m ² , Carboplatin AUC 5	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2	
NCT04813523	Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma	Adenocarcinoma of Esophagogastric Junction Neoadjuvant Chemotherapy Pembrolizumab	Drug: Pembrolizumab Injection [Keytruda]	Tianjin Medical University Cancer Institute and Hospital	Phase 2	
NCT04810910	Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy	Resectable Pancreatic Cancer	Biological: iNeo-Vac-P01 Other: GM-CSF	Zhejiang Provincial People's Hospital Hangzhou Neoantigen Therapeutics Co., Ltd.	Phase 1	
NCT04807140	Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)	Head and Neck Squamous Cell Carcinoma	Drug: Toripalimab, nab-paclitaxel, carboplatin Drug: Toripalimab Procedure: Surgical resection	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	
NCT04804696	Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Cancer	Drug: Toripalimab Drug: Paclitaxel Drug: Cisplatin	Peking University	Phase 2	
NCT04799314	PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT	Lymphoma, Large B-Cell, Diffuse Transplantation Chemotherapy	Drug: PD-1 Inhibitor Tislelizumab maintenance therapy	Ruijin Hospital	Phase 3	
NCT04794972	A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors	Glioma Solid Tumor	Drug: GNC-039	Sichuan Baili Pharmaceutical Co., Ltd. SystImmune Inc.	Phase 1	

해외 바이오의약품 임상 현황 (2021.3.29~2021.4.4)

한국바이오의약품협회, 2021.4.6.

출처: ClinicalTrials.gov

NCT04789434	PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT	Lymphoma, Large B-Cell, Diffuse Transplantation Chemotherapy	Drug: PD-1 Inhibitor Tislelizumab maintenance therapy	Ruijin Hospital	Phase 3	-----
NCT04781686	Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer	Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma	Drug: Camrelizumab Drug: Apatinib Mesylate Drug: S1 Drug: Docetaxel injection	Zhou Fuxiang Hubei Cancer Hospital Henan Provincial People's Hospital Huangshi Central Hospital Zhongnan Hospital	Phase 2	-----
NCT04768608	PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer	Castrate-Resistant Prostate Cancer	Drug: PD1-PSMA-CART cells	Zhejiang University Bioray Laboratories	Phase 1	-----
NCT04749641	Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma	Diffuse Intrinsic Pontine Glioma	Biological: Histone H3.3-K27M Neoantigen Vaccine Therapy	Yang Zhang Guangdong TCRCure Biopharma Technology Co., Ltd TCRCURE BIOPHARMA LTD.CHONGQING Beijing Tiantan Hospital	Phase 1	-----
NCT04706312	Transplantation of hAMSCs for Woman With DOR	Diminished Ovarian Response	Other: stem cells	The First Affiliated Hospital with Nanjing Medical University	Phase 1	-----
NCT04742153	A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)	Advanced or Metastatic Breast Cancer	Drug: MRG002	Shanghai Miracogen Inc.	Phase 2	-----
NCT04723030	The Transformation of Locally Advanced Pancreatic Cancer.	Locally Advanced Pancreatic Cancer	Drug: carlelizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)	Peking University	Phase 2	-----
NCT04550624	Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma	Advanced Cholangiocarcinoma	Drug: Pembrolizumab Injection [Keytruda] Drug: Lenvatinib Mesylate	Shanghai Jiahui International Hospital Shanghai Zhongshan Hospital	Phase 2	-----
NCT04797013	Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-II (TRACE II)	Acute Ischemic Stroke	Drug: rt-PA Drug: rhTNK-TPA	Beijing Tiantan Hospital Guangzhou Recomgen Biotech Co., Ltd.	Phase 3	-----
NCT04712643	A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Atezolizumab Drug: Bevacizumab Device: Transarterial chemoembolization (TACE)	Hoffmann-La Roche	Phase 3	-----
NCT04749368	Study to Investigate the Safety and Efficacy of BR11-835 and BR11-179 Combination Therapy Treating Chronic HBV Infection	Hepatitis B, Chronic	Drug: BR11-835 (VIR-2218) Biological: BR11-179 (VBI-2601) with IFN-α	Brii Biosciences Limited Vir Biotechnology, Inc. VBI Vaccines Inc.	Phase 2	-----
NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	Non-alcoholic Steatohepatitis	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	-----

○ 일본 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04798586	Study of PF 06863135 in Japanese Participants With Multiple Myeloma	Relapsed or Refractory Multiple Myeloma	Drug: PF-06863135	Pfizer	Phase 1	-----
NCT04676477	Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer (NSCLC)	Drug: Patritumab deruxtecan Drug: Osimertinib	Daiichi Sankyo, Inc.	Phase 1	-----
NCT03878953	A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism	Chronic Hypoparathyroidism	Drug: rhPTH(1-84)	Shire	Phase 3	-----
NCT04822181	Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	Non-alcoholic Steatohepatitis	Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	-----
NCT04712643	A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Atezolizumab Drug: Bevacizumab Device: Transarterial chemoembolization (TACE)	Hoffmann-La Roche	Phase 3	-----
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	-----
NCT04683003	A Continuation Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With TAK-755	Congenital Thrombotic Thrombocytopenic Purpura	Biological: TAK-755	Takeda Shire	Phase 3	-----